PTC Therapeutics price target raised to $85 from $82 at RBC Capital
RBC Capital raised the firm's price target on PTC Therapeutics to $85 from $82 and keeps a Sector Perform rating on the shares as part of a broader research note previewing Q2 earnings in Biotech. The biotech sector has picked up considerable momentum, with a near-unprecedented two-week move in June relative to the S&P